Novartis Vaccines and Diagnostics S.r.l.

Link copied
Case Copied 11 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Novartis Vaccines and Diagnostics S.r.l. [2015] APO 2

Patent Application:                2002330681

Title:Vaccines comprising aluminium adjuvants and histidine

Patentee:  Novartis Vaccines and Diagnostics S.r.l.

Delegate:  Dr B. Akhurst

Decision Date:  2 February 2015

Hearing Date:  28 November 2014

Catchwords:  PATENTS – section 70 – extension of term – s 70(2)(b) –whether a pharmaceutical substance when produced by a process that involves the use of recombinant DNA technology, falls within the scope of the claims – extension application accepted. 

Representation:  Patentee: Peter Maddigan of Counsel and Paul Whenman, patent attorney of FB Rice

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2002330681

Title:Vaccines comprising aluminium adjuvants and histidine

Patentee:  Novartis Vaccines and Diagnostics S.r.l.

Date of Decision:                   2 February 2015

DECISION

I accept the request for an extension of term of the patent. 

REASONS FOR DECISION

Background

  1. Patent application number 2002330681 was filed on 26 July 2002 and granted on 8 September 2008.  The date of the patent is 26 July 2002 and its 20 year term would expire on 26 July 2022.  On 13 February 2014 the patentee, Novartis Vaccines and Diagnostics S.r.l. (Novartis), applied for an extension of term of the patent based on the inclusion of the product Bexsero® on the Australian Register of Therapeutic Goods (ARTG). 

  2. During prosecution of the extension request, Novartis accepted that the application did not satisfy s 70(2)(a) of the Patents Act 1990 (the Act) and relied instead on s 70(2)(b).  However, a delegate of the Commissioner did not think the complete specification satisfied s 70(2)(b) because the processes set out in the claims did not require the involvement of recombinant DNA technology.  The delegate maintained this objection despite submissions to the contrary by Novartis, who requested an oral hearing.  The matter was heard in Canberra on 28 November 2014.

    The relevant law

  3. Part 3 of Chapter 6 of the Patents Act 1990 (the Act) provides the statutory framework for the extension of the term of standard patents relating to pharmaceutical substances.  Section 70 relevantly provides:

    “(1)The patentee of a standard patent may apply to the Commissioner for an extension of the term of the patent if the requirements set out in subsections (2), (3) and (4) are satisfied.

    (2) Either or both of the following conditions must be satisfied:

    (a)   one or more pharmaceutical substances per se must in substance be disclosed in the complete specification of the patent and in substance fall within the scope of the claim or claims of that specification;

    (b)   one or more pharmaceutical substances when produced by a process that involves the use of recombinant DNA technology, must in substance be disclosed in the complete specification of the patent and in substance fall within the scope of the claim or claims of that specification.”

  4. The expression “pharmaceutical substance” is defined in Schedule 1 of the Act:

    “pharmaceutical substance means a substance (including a mixture or compound of substances) for therapeutic use whose application (or one…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novartis Vaccines and Diagnostics S.r.l. and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] APO 2
Decision Date

CaseChat Overview and Summary

Novartis Vaccines and Diagnostics S.r.l. applied for an extension of the term of their Australian patent number 2002330681, titled "Vaccines comprising aluminium adjuvants and histidine." The dispute centred around whether the patent satisfied the statutory requirements under the Patents Act 1990 for an extension of term, particularly in relation to section 70(2)(b) of the Act. The key issue was whether the complete specification of the patent disclosed a pharmaceutical substance when produced by a process involving recombinant DNA technology, and whether this substance fell within the scope of the patent claims. The matter was heard by Dr B. Akhurst on 28 November 2014, with the decision handed down on 2 February 2015.

The court considered the statutory language of section 70(2)(b) of the Patents Act, which requires the disclosure of a pharmaceutical substance produced by a process involving recombinant DNA technology. The court agreed with the broader interpretation of this section, as adopted by the Deputy Commissioner in ImmunoGen, Inc. (ImmunoGen) [2014] APO 88, that the legislation encompasses scenarios where the process includes recombinant DNA technology without necessitating an explicit limitation of the claim to a recombinantly-produced product. The court found that the complete specification of the patent provided a real and reasonably clear disclosure of the pharmaceutical substance produced by a process involving recombinant DNA technology. The substance in question was identified as a mixture of protein antigens, aluminium hydroxide, and histidine, which met the statutory definition of a pharmaceutical substance. Furthermore, the court concluded that this substance, when produced by a process involving recombinant DNA technology, was included within the scope of the patent claims, specifically claim 20.

The court also confirmed that the Bexsero® products listed on the Australian Register of Therapeutic Goods met the requirements of subsections 70(3) and 70(4) of the Act. These subsections require that the pharmaceutical substance must be included in the ARTG and that the period between the patent date and the first regulatory approval date must be at least five years. The court accepted the extension request, noting that all statutory requirements had been satisfied. This decision was in line with the statutory provisions under subsection 74(1) and required the Commissioner to notify the applicant in writing, which was subsequently published.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.